logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn looks to schedule emergency Type C meeting with FDA on back of new breast cancer data

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company will request an emergency Type C meeting with the FDA to enroll 50 patients with solid tumor cancer conditions. 

Pourhassan says the Vancouver, Washington-based company was inspired by “very strong data” from its clinical trials evaluating its lead drug leronlimab for the treatment of metastatic triple-negative breast cancer and metastatic breast cancer. 

Quick facts: CytoDyn Inc.

Price: 4.01 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.09 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn reveals latest mild-to-moderate coronavirus patient data in Phase 2...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan says its drug leronlimab showed early clinical improvement in mild-to-moderate coronavirus patients in a recently completed Phase 2 trial. Pourhassan says in patients with a Total Clinical Symptom Score of 4 or more, with higher scores indicating...

1 day, 3 hours ago

2 min read